Safety with interferon in skin carcinomas (SCIENCE study)
- Conditions
- Skin Carcinomas Eyelid (Basal cell and Squamous Cell Ccarcinoma)
- Registration Number
- RPCEC00000143
- Lead Sponsor
- Center for Genetic Engineering and Biotechnology (CIGB)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 12
1. Compliance with the diagnostic criteria. 2. Injury Treatment virgins over 1 cm in which no surgical treatment is recommended (by extent of injury or post-surgical cosmetic results) or lesions with incomplete excision with previous surgical treatment or recurrent lesions. 3. Any stage, clinical subtype and skin phototype. 4. Location eyelid. 5. Age equal or higher than 18 years. 6. Voluntariness of the patient by signing the informed consent.
1. Decompensated chronic illness (asthma, diabetes mellitus, heart failure, hypertension, hyperthyroidism). 2. History or symptoms of stroke (ischemic, stroke). 3. History of allergy to any ingredient in the formulation under study. 4. Pregnancy, postpartum or breastfeeding women. 5. Mental incapacity to give consent obvious and act accordingly to the study. 6. Chronic arterial insufficiency reported by patients and verified by physical examination. 7. Severe hematological disorders, checked by complementary laboratory. 8. Diseases with metabolic involvement (liver diseases, kidney diseases, pancreatopatías, collagenopathies) reported by the patient. 9. Patients treated with steroids, immunosuppressants, IFN alpha or gamma in the last three months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method